STOCK TITAN

Becton, Dickinson and Co. - BDX STOCK NEWS

Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.

Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.

BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.

Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.

In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.

BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.

Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.

With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has completed its acquisition of Parata Systems, enhancing its presence in the pharmacy automation market valued at $600 million, projected to grow to $1.5 billion within a decade.

This acquisition aligns with BD's innovation strategy and aims to drive smart, connected care. The Parata portfolio will augment BD's Medication Management Solutions, addressing industry challenges such as clinician shortages and increased demand on pharmacy services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) will report its financial results for the third quarter of fiscal year 2022 on August 4, 2022, at 6:30 a.m. ET. The report will include summary financial information from the quarter ending June 30, 2022. An audio webcast will follow at 8 a.m. ET, discussing the results and operational updates. BD remains a leading global medical technology company, committed to improving health care through innovative solutions and technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
Rhea-AI Summary

BD (Becton, Dickinson and Company) has appointed Rishi Grover as the new executive vice president and chief integrated supply chain officer, effective July 7, 2022. Grover, who brings over 20 years of experience in manufacturing and supply chain, previously held senior roles at Carrier. He will oversee Supply Chain, Operations, Procurement, Sustainability, and EHS teams and will be part of the BD Executive Leadership Team. Grover succeeds Alexandre Conroy, who is retiring after 31 years with the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has received CE marking for its BD MAX™ Respiratory Viral Panel (RVP), a diagnostic test that detects SARS-CoV-2, Influenza A + B, and RSV using a single nasal or nasopharyngeal swab. This test enhances diagnostic efficiency, crucial during flu season, by enabling quick differentiation and treatment for these viruses. The BD MAX™ System, which supports this assay, is widely utilized globally for various diagnostic tests. BD plans to seek Emergency Use Authorization from the FDA shortly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
covid-19
Rhea-AI Summary

BD (Becton, Dickinson and Company) has announced a voluntary recall of certain lots of Intraosseous Needle Set Kits, Manual Driver Kits, and Powered Drivers. The recall is due to potential issues that could lead to difficulty in needle assembly removal, failure of safety mechanisms, and functional loss of intraosseous access. These defects may cause delays in patient care or increase the risk of needlestick injuries. BD advises customers to review their inventory and temporarily halt usage until further notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) announced a collaboration with Mayo Clinic Platform to access a vast collection of de-identified clinical data to enhance post-market surveillance of its products. This partnership aims to accelerate innovation, improve patient care, and leverage real-world data for insights beyond traditional clinical trials.

The Mayo Clinic Platform offers access to data from 10 million patients, including extensive lab results and clinical notes. BD plans to utilize advanced analytics and predictive modeling to enhance product development and regulatory submissions, ultimately improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
-
Rhea-AI Summary

CerTest Biotec and BD (Becton, Dickinson and Company) (NYSE: BDX) have partnered to develop a RT-PCR detection kit for the Monkeypox virus using the BD MAX™ Molecular Diagnostic System. This collaboration aims to leverage the BD MAX™ open system reagent suite to validate the CerTest VIASURE Monkeypox CE/IVD test, enhancing user access to confirmatory testing. The BD MAX™ System can process up to 24 samples in under three hours, streamlining diagnostics for various infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
Rhea-AI Summary

BD (Becton, Dickinson and Company) has appointed Simon Campion as the new executive vice president and president of its Medical segment, effective July 1, 2022. Campion, who has extensive experience with BD and previously led the Interventional segment, succeeds Alberto Mas who is retiring. His role will focus on the operational and commercial performance of the Medical segment, aligned with BD’s 2025 strategy. Campion holds a Ph.D. in Mechanical Engineering and an MBA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none

FAQ

What is the current stock price of Becton, Dickinson and Co. (BDX)?

The current stock price of Becton, Dickinson and Co. (BDX) is $226.95 as of December 24, 2024.

What is the market cap of Becton, Dickinson and Co. (BDX)?

The market cap of Becton, Dickinson and Co. (BDX) is approximately 65.6B.

What does Becton, Dickinson and Company (BD) specialize in?

BD specializes in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products.

What are BD's main business segments?

BD’s main business segments include BD Medical, BD Life Sciences, and BD Interventional.

What recent projects has BD undertaken?

BD has collaborated on recycling used blood collection tubes in Denmark and launched new cell sorters for enhanced research in cell biology, cancer, and immunology.

How much of BD's revenue comes from international markets?

International revenue accounts for 43% of BD's total business.

What significant acquisition has BD announced recently?

BD announced the acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion.

How many employees does BD have?

BD has over 70,000 employees globally.

Where can I find more information about BD's financial performance?

Information about BD's financial performance can be found on their investor relations website at www.bd.com/investors.

What is the significance of the BD FACSDiscover™ S8 Cell Sorters?

The BD FACSDiscover™ S8 Cell Sorters enable real-time imaging and spectral flow cytometry, allowing researchers to gain new insights in various scientific fields.

Which regulatory body recently issued a safety communication regarding syringes?

The U.S. Food and Drug Administration (FDA) issued the safety communication.

What is BD's approach to sustainability?

BD is committed to sustainable innovation, including collaborations to recycle medical plastics and initiatives to minimize its environmental footprint.

Becton, Dickinson and Co.

NYSE:BDX

BDX Rankings

BDX Stock Data

65.62B
288.35M
0.28%
91.75%
0.73%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
FRANKLIN LAKES